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This study evaluated the in vitro effect of sulfamethoxazole-trimethoprim against Histoplasma capsulatum var.
capsulatum isolated from HIV-positive patients. The drugs were tested by microdilution testing in accordance
with the CLSI guidelines. All of the strains were inhibited by sulfamethoxazole-trimethoprim, with MIC ranges
of 0.039 (sulfamethoxazole)/0.0078 (trimethoprim) mg/ml to 0.625/0.125 mg/ml for mycelial forms and 0.0025/
0.0005 to 0.02/0.004 mg/ml for yeast-like forms. However, in vivo studies are necessary to evaluate the
significance of these results.
Histoplasmosis is an infection caused by the dimorphic fun-
gus Histoplasma capsulatum. It is endemic in the Americas (3)
and is currently one of the most important systemic infections
in Brazil (6). In a retrospective study carried out in Ceara´ state
(northeastern Brazil) from 1995 to 2004, 164 histoplasmosis
cases were found in HIV-positive patients (4).
The treatment of histoplasmosis depends on the infection’s
severity and clinical manifestation, along with individual risk
factors (9, 13). Because of the increase in histoplasmosis, par-
ticularly in HIV-positive patients, as well as the development
of antifungal resistance associated with refractory and re-
peated infections (13), there is a need for seeking new thera-
peutic options for this mycosis. Therefore, this study aimed at
testing the in vitro activity of sulfamethoxazole-trimethoprim
(SMX-TMP) against H. capsulatum var. capsulatum strains
isolated from AIDS patients.
A total of 84 clinical strains of H. capsulatum isolated from
two different biogeographic regions in Brazil were included in
this study. Of them, 68 came from Ceara´ (northeastern semi-
arid region) and 16 from southeastern states (a subtropical
region). The strains were obtained from the collection of the
Specialized Medical Mycology Center of Ceara´ Federal Uni-
versity and were handled in our level 3 biosecurity laboratory.
For each strain, a combined solution of SMX-TMP (Roche,
Brazil) was used at a concentration range of 0.0025 mg/ml
SMX/0.0005 mg/ml TMP and 20/4 mg/ml. The inocula were
prepared as described by Li et al. (10), with some modifica-
tions. Briefly, H. capsulatum strains were cultured in the my-
celial phase onto brain heart infusion (BHI) agar for 7 days at
28°C, and then 2 ml of sterile saline was added to each culture.
The surfaces of the mycelia were harvested with a swab. To
obtain yeast cells, isolates were cultured on agar BHI with
sheep blood (10%) at 35°C and were maintained through
weekly passages (7). The supernatant was read in a spectro-
photometer at 530 nm, and the transmittance was adjusted to
90 to 95%. The suspensions then were diluted to obtain an
inoculum of 0.5  103 to 2.5  104 CFU/ml, as demonstrated
by quantitative colony counts on Sabouraud dextrose agar (10).
Susceptibility tests were carried out as described by Nakai et al.
(11), except that the readings were performed after 7 or 4 days
for mycelial and yeast growth, respectively. For SMX-TMP,
the MIC was defined as the lowest concentration at which no
visible growth was observed (14). The differences in the MICs
between northeastern and southeastern strains were evaluated
by Student’s t test (P  0.05). Susceptibility control tests were
performed with amphotericin B (AMB) against 84 and 7 H.
capsulatum strains in mycelial and yeast-like forms, respec-
tively. SMX-TMP quality control was carried out with Esche-
richia coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853.
All H. capsulatum strains were inhibited by SMX-TMP, with
MICs ranging from 0.039/0.0078 to 0.625/0.125 mg/ml for the
mycelial forms and 0.0025/0.0005 to 0.02/0.004 mg/ml for the
yeast-like forms. The SMX-TMP MICs for strains from north-
eastern Brazil presented geometric means of 0.1544 mg/ml for
sulfamethoxazole and 0.0309 mg/ml for trimethoprim for the
mycelial forms and 0.0141 mg/ml for sulfamethoxazole and
0.0028 mg/ml for trimethoprim for yeast-like forms. The geo-
metric means for the strains from southeast Brazil were 0.1152
mg/ml for sulfamethoxazole and 0.0230 mg/ml for tri-
methoprim for the mycelial forms and 0.0079 mg/ml for sulfa-
methoxazole and 0.0016 mg/ml for trimethoprim for yeast-like
forms (Table 1).
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Susceptibility control tests showed MICs (geometric means)
of 0.1168 and 0.0762 g/ml for AMB against H. capsulatum for
mycelial and for yeast-like forms, respectively. E. coli ATCC
25922 was sensitive and P. aeruginosa ATCC 27853 was resis-
tant to SMX-TMP.
Previous studies have described the effect of sulfamethox-
azole or SMX-TMP against other pathogenic fungi, such as
Cryptococcus neoformans (8) and Aspergillus fumigatus (1). The
results of this study demonstrated for the first time the inhib-
itory effect of SMX-TMP against H. capsulatum. They show
that the MICs for strains from northeastern Brazil were higher
than those from the southeast. These findings can be related to
population profile and/or geoclimatic differences, but further
investigation is necessary to explain these hypotheses. The
medium composition also may alter the drug effect. H. capsu-
latum strains were inhibited by SMX-TMP diluted in RPMI
medium. Yeast nitrogen base (YNB) was not used because no
growth of H. capsulatum was obtained in this medium (data not
shown). If H. capsulatum had grown in YNB medium, the
MICs of SMX-TMP probably would have been lower than
those observed. Afeltra et al. (1) studied the effectiveness of
sulfonamides against Aspergillus spp. and demonstrated the
influence of the composition of the medium in susceptibility
tests with SMX-TMP, observing that RPMI, despite being rec-
ommended by the CLSI (12), contains four times more p-
aminobenzoic acid (PABA) than YNB medium according to
the manufacturer. Based on Hanafy et al. (8), in a study using
sulfamethoxazole against strains of Cryptococcus spp., MICs
varied from 0.125 to 0.250 mg/ml in RPMI medium, while in
media not containing PABA (such as YNB) or compounds
related to PABA, the MICs declined to 0.031 to 0.062 mg/ml
(8). MICs for H. capsulatum yeast-like forms were lower than
those for mycelial forms for both northeastern (P  0.0000)
and southeastern (P  0.0001) strains.
SMX-TMP has shown good results in the treatment of para-
coccidioidomycosis as a supportive therapy after the adminis-
tration of amphotericin B and when there is an involvement of
the central nervous system. The sulfonamides remain the drugs
of choice to treat paracoccidioidomycosis in developing coun-
tries with substandard socioeconomic conditions. SMX-TMP
also is used to treat fungal infections caused by Pneumocystis
jiroveci in HIV-positive patients in our region, but this combi-
nation, with or without antifungals, has never been used to
treat histoplasmosis.
Until this study, there had been no reports of the efficacy of
SMX-TMP against H. capsulatum var. capsulatum. However,
there are reports of histoplasmosis caused by Histoplasma cap-
sulatum var. duboisii in Africa being successfully treated with
SMX-TMP (2, 5). Therefore, despite the evidence in this study,
in vivo studies are necessary to evaluate the significance of
these results.
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TABLE 1. MICs of SMX/TMP against strains of H. capsulatum var.
capsulatum in yeast-like and mycelial forms from northeastern and
southeastern Brazila
SMX-TMP
MICs (mg/ml)
No. of NE strains No. of SE strains
M Y M Y
0.0025/0.0005 1
0.005/0.001 2
0.01/0.002 1
0.02/0.004 6 1
0.039/0.0078 2 2
0.078/0.0156 14 6
0.156/0.0312 37 5
0.312/0.0625 13 3
0.625/0.125 2
Total 68 8 16 3
a Geometric mean MICs for mycelial (M) and yeast-like (Y) forms of strains
from northeastern (NE) Brazil were 0.1544/0.0309 and 0.0141/0.0028 mg/ml,
respectively. Geometric mean MICs for mycelial and yeast-like forms of strains
from southeastern (SE) Brazil were 0.1152/0.0230 and 0.0079/0.0016, respec-
tively.
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